The fact that no clinically meaningful benefit in PD patients in two double-blind studies was reported, is discouraging, but this can find an explanation by the fact that nilotinib does not accumulate in the brain at concentrations sufficient to inhibit c-Abl. Here, ABL1 is linked to Parkinson disease.